BSEBoard Meeting6d ago · 6 Aug 2026, 03:30 pm

Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1.Unaudited Financial ....

Aspira Pathlab & Diagnostics Ltd · 540788

✦ AI SummaryResults

Aspira Pathlab & Diagnostics Ltd has scheduled a board meeting on August 12, 2026, to consider and approve unaudited financial results for the first quarter ended June 30, 2026, and to consider a proposal for raising funds through a preferential issue of equity shares or warrants.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Approval Of Un-Audited Financial Result (Standalone) For The First Quarter Ended On June 30,2026 And To Transact Other Businesses

Attachments (1)

📄

05c193a0-6922-4a75-9fc2-7e8c199cce06.pdf

pdf

Download →
View document text
Aspira Pathlab & Diagnostics Limited Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086 Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086 CIN: L85100MH1973PLC289209 Date: August 6, 2026 Listing Department BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001. Security Code: 540788 Security ID: ASPIRA Sub: Intimation of the Board Meeting Ref: Prior Intimation under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Amended (“SEBI Listing Regulations”) - Board Meeting to be held on August 12, 2026 Dear Sir/Madam, This is to inform you that pursuant to regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, August 12, 2026 inter alia, 1.To consider and approve the Un-Audited Financial Results (Standalone) of the Company for the first quarter ended June 30, 2026. 2. To consider, evaluate and if deem fit to approve the proposal for raising of funds by way of issuance of one or more instruments including equity shares or warrants convertible into equity shares of the Company through preferential issue, private placements, rights issue or any other methods or combination thereof as may be permitted with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended, subject to requisite approvals including shareholders and statutory approvals. 3. To transact other incidental and ancillary matters as may be decided by the board. The notice of the said Board Meeting will also be uploaded on the Company’s website www.aspiradiagnostics.com as per regulation 46(2)(l)(i) of the Listing Regulations. Kindly take the same on your record. Thanking You. Yours faithfully, For Aspira Pathlab & Diagnostics Limited Nikunj Mange Executive Director DIN: 08489442 INDIA’S FIRST 0227197 5756, 022 2513 9090 www.aspiradiagnostics.com FULLY INTEGRATED LAB support@aspiradiagnostics.com │info@aspiradiagnostics.com